University of Health Sciences Turkey, Beyoglu Eye Training and Research Hospital, Bereketzade Street Number: 2, Beyoglu, Istanbul, Turkey.
Int Ophthalmol. 2022 Sep;42(9):2829-2840. doi: 10.1007/s10792-022-02273-x. Epub 2022 Apr 2.
To investigate the results of surgical management of glaucoma following different keratoplasty techniques.
Medical records of 628 cases who underwent keratoplasty were reviewed. One hundred and eighty-eight patients (29.9%) who developed post-keratoplasty glaucoma were evaluated. Patients who could not be controlled with maximal medical treatment and underwent glaucoma surgery were included in this study. Trabeculectomy, Ahmed glaucoma valve (AGV) implantation or diode laser cyclophotocoagulation (DLC) were applied.
Glaucoma surgery was performed in 55 (29.3%) patients who had uncontrolled post-keratoplasty glaucoma. In penetrating keratoplasty group (n = 42), DLC was applied to 30 (71.4%) eyes, AGV to 11 (26.2%) eyes, and trabeculectomy in 1 (2.4%) eye. In Descemet's membrane endothelial keratoplasty group (n = 8), DLC was applied to 4 (50%) eyes, trabeculectomy for 3 (37.5%) eyes and AGV for 1 (12.5%) eye. In deep anterior lamellar keratoplasty group (n = 5), DLC was applied to 2 (40%) eyes, trabeculectomy to 2 (40%) eyes and AGV to 1 (20%) eye. While a statistically significant decrease was found in intraocular pressure (IOP) and anti-glaucomatous medication after surgery (p < 0.05 for each), no significant difference was found in best corrected visual acuity (BCVA). During follow-up, DLC was applied as re-glaucoma surgery in 19 (34.5%) cases. A significant reduction in IOP together with number of anti-glaucomatous medications was found with re-operation; however, a significant decrease in BCVA was noted (p < 0.05 for each).
Glaucoma surgeries after keratoplasty are effective in decreasing IOP and the number of anti-glaucomatous medication. While BCVA doesn't change after the first glaucoma surgery, after re-operation significant decrease may occur.
研究不同角膜移植术后青光眼手术治疗的结果。
回顾了 628 例接受角膜移植术患者的病历。评估了 188 例(29.9%)发生角膜移植术后青光眼的患者。本研究纳入了经最大药物治疗仍无法控制且接受青光眼手术的患者。应用小梁切除术、 Ahmed 青光眼引流阀(AGV)植入术或二极管激光睫状体光凝术(DLC)。
55 例(29.3%)角膜移植术后青光眼未控制的患者接受了青光眼手术。在穿透性角膜移植组(n=42)中,30 只眼(71.4%)应用 DLC,11 只眼(26.2%)应用 AGV,1 只眼(2.4%)应用小梁切除术。在 Descemet 膜内皮角膜移植组(n=8)中,4 只眼(50%)应用 DLC,3 只眼(37.5%)应用小梁切除术,1 只眼(12.5%)应用 AGV。在深层前弹力层角膜移植组(n=5)中,2 只眼(40%)应用 DLC,2 只眼(40%)应用小梁切除术,1 只眼(20%)应用 AGV。术后眼压(IOP)和抗青光眼药物均显著降低(p<0.05),最佳矫正视力(BCVA)无显著差异。随访中,19 例(34.5%)再次行 DLC 手术作为再发性青光眼手术。再次手术时,眼压和抗青光眼药物的数量均显著降低;然而,BCVA 显著下降(p<0.05)。
角膜移植术后青光眼手术可有效降低眼压和抗青光眼药物的使用量。初次青光眼手术后 BCVA 无变化,但再次手术后可能会显著下降。